针对偏头痛的与素基因相关的类向疗法
Stephanie Barnes1,2,3,4,5,6,7, Lucie Aldous1,2,3,4,5,6,7, Bronwyn Jenkins1,2,3,4,5,6,7
1Hornsby Ku-ring-gai Hospital, Sydney.
Australian prescriber
|May 9, 2025
概括
素基因相关 (CGRP) 向治疗提供了新的偏头痛预防选择. 这些包括CGRP单克隆抗体和小分子,目前正在研究它们的长期有效性和使用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 素基因相关 (CGRP) 在偏头痛病理生理学中起着至关重要的作用.
- 针对CGRP的治疗方法代表了一种新的偏头痛预防药物类别.
研究的目的:
- 审查目前针对偏头痛预防的CGRP向疗法的现状.
- 讨论不同类别,施用方法和支持这些治疗的临床数据.
主要方法:
- 对CGRP单克隆抗体的临床试验和现实世界的数据的审查.
- 小分子CGRP受体对抗剂 (gepants) 的概述.
- 检查治疗可访问性,包括澳大利亚的制药福利计划 (PBS) 清单.
主要成果:
- 在过去的十年中,CGRP单克隆抗体在偶发性和慢性偏头痛预防方面已经证明了其有效性和安全性.
- 小分子可用于预防和急性偏头痛治疗,其作用在不断发展.
- 在澳大利亚获得CGRP单克隆抗体的补贴需要先接受其他预防药物的治疗.
结论:
- 针对CGRP的治疗方法,包括单克隆抗体和gepants,是偏头痛管理的重大进展.
- 目前正在进行进一步的研究,以评估这些药物的长期安全性,并扩大这些药物的治疗应用.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
137
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
137
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Antiepileptic Drugs: Glutamate Antagonists
249
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
249
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
151
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
151


